# US 2022/0031855 A1 · Organic Anion Transporting Peptide-Based Cancer Imaging and Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031855 A1
- Document ID: US20220031855A1
- Status: Published application
- Kind: A1
- Application number: 17/318,802
- Filed: 2021-05-12
- Published: 2022-02-03
- Earliest claimed: 2014-12-22
- Assignees: Da Zen Theranostics, Inc.
- Applicants: Da Zen Theranostics, Inc.
- Inventors: Leland W.K. Chung
- Web page: https://patentgrep.com/patent/US20220031855A1

## CPC

- A61K 47/558: {the modifying agent being a chemiluminescent acceptor}
- A61K 51/0446: {having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil}
- A61P 35/00: Antineoplastic agents
- C09B 23/0066: {the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61K 49/0017: {Fluorescence in vivo}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A dye-drug conjugate for preventing, treating, or imaging cancer having the following structure: wherein R1 and R2 are independently selected from the group consisting of —H, alkyl, alkyl-sulphonate, alkylcarboxylic, alkylamino, aryl, —SO3H, —PO3H, —OH, —NH2, and -halogen; wherein Y1 and Y2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, ω-alkylaminium, ω-alkynyl, PEGyl, PEGylcarboxylate, ω-PEGylaminium, ω-acyl-NH, ω-acyl-lysinyl-, ω-acyl-triazole, ω-PEGylcarboxyl-NH—, ω-PEGylcarboxyl-lysinyl, and ω-PEGylcarboxyl-triazole; wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH2, SH and OH; and R3 and R4 are independently a hydrogen, a therapeutic agent, or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle, wherein the imaging is a radio-isotope selected from the group consisting of F18, I-125, I-124 I-123, I-131, and small molecule labeled with any of these isotopes, or wherein the imaging moiety is a chelator-complexed radioactive isotope, wherein the radioactive isotope is selected from the group consisting of Cu-64, In-111, Tc-99m, Ga-68, Lu-177, Zo-89, Th-227 and Gd-157.

## Claims

### Claim 1

A dye-drug conjugate comprising the following structure:
wherein R1 and R2 are independently selected from the group consisting of —H, alkyl, alkyl-sulphonate, alkylcarboxylic, alkylamino, aryl, —SO3H, —PO3H, —OH, —NH2, and -halogen;
wherein Y1 and Y2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, ω-alkylaminium, ω-alkynyl, PEGyl, PEGylcarboxylate, ω-PEGylaminium, ω-acyl-NH, ω-acyl-lysinyl-, ω-acyl-triazole, ω-PEGylcarboxyl-NH—, ω-PEGylcarboxyl-lysinyl, and ω-PEGylcarboxyl-triazole;
wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH2, SH and OH; and
R3 and R4 are independently a hydrogen, a therapeutic agent and/or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle,
wherein the imaging is a radio-isotope selected from the group consisting of F18, I-125, I-124 I-123, I-131, and a small molecule labeled with any of these isotopes, or
wherein the imaging and/or therapeutic moiety is a chelator-complexed radioactive isotope, wherein the radioactive isotope is selected from the group consisting of Cu-64, In-111, Tc-99m, Ga-68, Lu-177, Zo-89, Th-227, and Gd-157.

### Claim 2 (depends on 1)

The dye-drug conjugate according to claim 1, wherein X is a halogen.

### Claim 3 (depends on 2)

The dye-drug conjugate according to claim 2, wherein X is chloro.

### Claim 4 (depends on 1, 2)

The dye-drug conjugate according to claim 1 or 2, wherein R3 comprises gemcitabine.

### Claim 5 (depends on 1, 2, 3)

The dye-drug conjugate according to any one of claims 1-3, wherein Rz comprises a therapeutic agent and R4 comprises an imaging moiety.

### Claim 6 (depends on 1, 2, 3)

The dye-drug conjugate according to any one of claims 1-3, wherein R3 comprises a first therapeutic agent and R4 comprises a second therapeutic agent.

### Claim 7 (depends on 1)

The dye-drug conjugate according to claim 1, wherein the dye-drug conjugate is one selected from the group consisting of:

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method for diagnosis of cancer using the dye-drug conjugate according to any one of claims 1-7.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, and hepatic cancer.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7)

A method for preventing or treating cancer using the dye-drug conjugate according to any one of claims 1-7.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the cancer is one selected from the group consisting of prostate cancer, breast cancer, renal cancer, pancreatic cancer, lung cancer, brain tumor, and hepatic cancer.
